Skip to content

Study · Not a test of the peptide alone · 2001

3 results

Antiproliferative effects of insulin-like growth factor-binding protein-3 in mesenchymal chondrogenic cell line RCJ3.1C5.18. relationship to differentiation stage.

Spagnoli A, Hwa V, Horton WA, Lunstrum GP, Roberts CT Jr, Chiarelli F, Torello M, Rosenfeld RG

The Journal of biological chemistry10 Nov 2000Cited by 54 (Europe PMC)

PMID11110782 (opens in a new tab)DOI10.1074/jbc.m005088200 (opens in a new tab)PepBankPUB-11110782
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Chondrogenesis results from a complex equilibrium between chondrocyte proliferation and differentiation. Insulin-like growth factors (IGFs) have a crucial role in chondrogenesis, but their mechanisms of action are not well defined. IGF-binding protein-3 (IGFBP-3) is the major carrier for circulating IGFs in postnatal life, and has been shown to have IGF-independent effects on proliferation of several cancer cell lines. In this study, we have evaluated the IGF-independent and -dependent effects of IGFBP-3 on chondrocyte proliferation and the relationship of these effects with chondrocyte differentiation stage. We used the RCJ3.1C5.18 nontransformed mesenchymal chondrogenic cell line, which, over 2 weeks of culture, progresses through the differentiation pathway exhibited by chondrocytes in the growth plate. We demonstrated that IGFBP-3 inhibited, in a dose-dependent manner (1-30 nm), the proliferation of chondroprogenitors and early differentiated chondrocytes, stimulated by des-(1-3)-IGF-I and longR(3)-IGF-I (IGF-I analogs with reduced affinity for IGFBP-3), and by insulin and IGF-I. In terminally differentiated chondrocytes, IGFBP-3 retained the ability to inhibit cell proliferation stimulated by IGF-I, but had no effect on cell growth stimulated by insulin, or des-(1-3)-IGF-I or longR(3)IGF-I. By monolayer affinity cross-linking, we demonstrated a specific IGFBP-3-associated cell-membrane protein of approximately 20 kDa. We determined that IGFBP-3 has an antiproliferative effect on chondrocytes and, that this effect is related to the differentiation process. In chondroprogenitors and early differentiated chondrocytes, antiproliferative effect of IGFBP-3 is mainly IGF-independent, whereas, following terminal differentiation this effect is IGF-dependent.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 01LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Efficacy outcome

    In RCJ3.1C5.18 chondroprogenitors, IGFBP-3 dose-dependently inhibited proliferation stimulated by des-(1-3)-IGF-I and other agents.

    In plain wordsIn cells, IGFBP-3 inhibited precursor cartilage cell proliferation stimulated by des-(1-3)-IGF-I and other agents, compared with stimulation alone.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseChondroprogenitor proliferation
    Study

    n: not reported in source

    RCJ3.1C5.18 chondrogenic cells
    Comparator
    IGF analogue stimulation without IGFBP-3
    Outcome group
    Cell proliferation and differentiation · Musculoskeletal

    Source sentences

    Summary
    We demonstrated that IGFBP-3 inhibited, in a dose-dependent manner (1-30 nm), the proliferation of chondroprogenitors and early differentiated chondrocytes, stimulated by des-(1-3)-IGF-I and longR(3)-IGF-I (IGF-I analogs with reduced affinity for IGFBP-3), and by insulin and IGF-I.
    1 context sentence
    Summary · context
    We used the RCJ3.1C5.18 nontransformed mesenchymal chondrogenic cell line, which, over 2 weeks of culture, progresses through the differentiation pathway exhibited by chondrocytes in the growth plate.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 02LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Efficacy outcome

    In early differentiated RCJ3.1C5.18 chondrocytes, IGFBP-3 dose-dependently inhibited proliferation stimulated by des-(1-3)-IGF-I and other agents.

    In plain wordsIn cells, IGFBP-3 inhibited early differentiated cartilage cell proliferation stimulated by des-(1-3)-IGF-I and other agents, compared with stimulation alone.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseEarly differentiated chondrocyte proliferation
    Study

    n: not reported in source

    RCJ3.1C5.18 chondrogenic cells
    Comparator
    IGF analogue stimulation without IGFBP-3
    Outcome group
    Cell proliferation and differentiation · Musculoskeletal

    Source sentences

    Summary
    We demonstrated that IGFBP-3 inhibited, in a dose-dependent manner (1-30 nm), the proliferation of chondroprogenitors and early differentiated chondrocytes, stimulated by des-(1-3)-IGF-I and longR(3)-IGF-I (IGF-I analogs with reduced affinity for IGFBP-3), and by insulin and IGF-I.
    1 context sentence
    Summary · context
    We used the RCJ3.1C5.18 nontransformed mesenchymal chondrogenic cell line, which, over 2 weeks of culture, progresses through the differentiation pathway exhibited by chondrocytes in the growth plate.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  3. 03LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Efficacy outcome

    In terminally differentiated chondrocytes, IGFBP-3 did not affect cell growth stimulated by des-(1-3)-IGF-I.

    In plain wordsIn cells, IGFBP-3 did not affect mature cartilage cell growth stimulated by des-(1-3)-IGF-I, compared with stimulation alone.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeTerminally differentiated chondrocyte growth
    Study

    n: not reported in source

    RCJ3.1C5.18 chondrogenic cells
    Comparator
    IGF analogue stimulation without IGFBP-3
    Outcome group
    Cell proliferation and differentiation · Musculoskeletal

    Source sentences

    Summary
    In terminally differentiated chondrocytes, IGFBP-3 retained the ability to inhibit cell proliferation stimulated by IGF-I, but had no effect on cell growth stimulated by insulin, or des-(1-3)-IGF-I or longR(3)IGF-I.
    1 context sentence
    Summary · context
    We used the RCJ3.1C5.18 nontransformed mesenchymal chondrogenic cell line, which, over 2 weeks of culture, progresses through the differentiation pathway exhibited by chondrocytes in the growth plate.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.